RxDoctor Payments Data

Peter Crisologo, DPM

Podiatrist · Dallas, TXNPI 1710306881

Payments from drug & device makers

What this record shows

This record is dominated by other: $3,620 of the $5,962 with a category attached, or 60.7%. Integra Lifesciences Corporation accounts for 60.7% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2022 at $3,892 and has fallen 99.5% since, to $18 in 2025.

$5,962in general payments, 2019–2025

Across 26 payments — averaging $229.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Integra Lifesciences Corporation$4K
  • Legacy Ortho LLC$1K
  • Stryker$699
  • Bone Support Inc.$142
  • Organogenesis Inc.$118
  • Sanara Medtech Inc.$106
  • plus $77 from 2 others
$37,751in research payments, 2019–2025

Across 13 payments — averaging $2903.92 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Biotissue Holdings Inc.$38K

What the payments were for

  • Speaking & faculty fees$1182%
  • Food & beverage$1,02417%
  • Education$1,20020%
  • Other$3,62061%

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,962 in reported general payments places this provider in the 75th percentile of 470 podiatrist providers in Texas.

See all podiatrist providers in Texas

Medicare billing

Part B allowed, 2024
$21,638
Medicare patients
47
Services billed
100

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other podiatrist in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →